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ABSTRACT
Objectives: The aim of this study was to evaluate by
meta-analysis the current level of evidence in order to
establish the impact of a platelet transfusion on
survival in patients on pre-injury antiplatelet agents
who sustain an intracranial haemorrhage (either
spontaneous or traumatic).
Design: This was a meta-analysis; the MEDLINE
Database was searched using the PubMed interface
and the Ovid interface. CINAHL and EMBASE
Databases were also searched. The search was
performed to identify randomised controlled trials
(RCT)’s case-controlled studies or nested case-
controlled studies. Comparing the outcome (death or
survival) of patients with intracranial haemorrhage
(ICH) and pre-injury antiplatelet agents who received
a platelet transfusion against a similar cohort of
patients who did not receive a platelet transfusion.
Results: 499 citations were obtained from the
PubMed search. 31 full articles were reviewed from
34 abstracts. 6 studies were found suitable for the
meta-analysis. No randomised controlled studies
were identiﬁed. 2 of the six studies were in patients
with spontaneous ICH. The remaining four studies
were in patients with traumatic intracranial
haemorrhage. Signiﬁcant heterogeneity was present
between the studies, I
2¼58.276. The random effects
model was therefore the preferred model, this
produced a pooled OR for survival of 0.773 (95% CI
0.414 to 1.442).
Conclusions: The results of this meta-analysis has
shown, based upon six small studies, that there was
no clear beneﬁt in terms of survival in the
administration of a platelet transfusion to patients
with antiplatelet-associated ICH. Further work is
required in order to establish any potential beneﬁt in
the administration of a platelet transfusion in patients
with spontaneous or traumatic intracranial
haemorrhage who were on pre-injury antiplatelet
agents.
INTRODUCTION
Antiplatelet agents, in particular aspirin and
clopidogrel, are an essential component of
treatment and prophylaxis for both cardio-
vascular disease and cerebrovasular; however,
they are both associated with a small risk of
intracranial haemorrhage (ICH). He et al
1
performed a meta-analysis of 16 clinical trials
and showed that aspirin treatment was asso-
ciated with an absolute risk increase of
haemorrhagic stroke of 12 events per 10000
persons (95% CI 5 to 20, p<0.001). With
regard to traumatic intracranial haemorrhage
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The aim of this meta-analysis was to determine the
impact on survival of a platelet transfusion in
patients on pre-injury antiplatelet agents with:




- Six studies were found to be suitable for the
meta-analysis (two studies for spontaneous ICH
and the remaining four were traumatic intracra-
nial haemorrhage).
- The pooled OR showed no beneﬁt in survival
following a platelet transfusion (OR¼0.773, 95%
CI 0.414 to 1.442).
Strengths and limitations of this study
- The studies were small, unpowered and not
randomised.
- Mortality is a relatively crude marker of effect in
the cohort of patients with either spontaneous or
traumatic haemorrhage.
- Signiﬁcant bias may have been introduced in
view of the fact that in all but one study, the
platelet transfusions were given at the discretion
of the attending physician.
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Open Access Research(TICH), early studies in this ﬁeld (Mack et al
2, Spektor
et al
3,J o n e set al
4) failed to demonstrate antiplatelet
agents as a risk factor for ICH in patients with blunt head
trauma. Fabbri et al
5 undertook a cohort study looking at
predictors for ICH on a database of 14288 head injury
patients. These authors found using multivariate logistic
regression that the combination of age over 65 years and
the use of antiplatelet agents statistically increased the
risk of ICH in their model. Pre-injury use of antiplatelet
agents alone was found to have an OR of 1.2 (95% CI 0.9
to 1.7, p¼0.202). Thus, it may well be that the combi-
nation of increased age plus use of antiplatelet agents
rather than antiplatelet agents in isolation increases the
risk of TICH as suggested by Fabbri et al.
5
McMillan and Rogers
6 proposed a protocol for the
administration of a platelet transfusion in patients with
TICH who were on pre-injury antiplatelet agents. The
authors, however admit, in their own review that the
evidence for this approach is lacking. A systematic review
by Beshay et al
7 provided an overview of the pharma-
cology of antiplatelet agents in the setting of intracranial
haemorrhage. Cambell et al
8 also provided a protocol for
correcting platelet dysfunction in antiplatelet-associated
ICH. These authors also recognised that the current
evidence for this approach is limited. The administration
of platelet transfusions is practiced in some trauma
centres for traumatic antiplatelet-associated ICH. The
aim of this study was to evaluate by meta-analysis the
current level of evidence in order to establish the impact
of a platelet transfusion on survival in patients on pre-
injury antiplatelet agents who sustain an intracranial
haemorrhage (either spontaneous or traumatic).
METHODS
The MEDLINE Database was searched using the PubMed
interface. The following search terms were used: (1) Head
injury AND antiplatelet agents.( 2 )Intracranial haemorrhage
AND platelet transfusion.C a s e econtrol and nested casee
control studies comparing the cohort who were given
platelet transfusions against the cohort who had not were
included in the meta-analysis. The search strategy was run
several times during the development of the paper in
order to ensure that all the relevant papers were captured
up to the date of submission. The ﬁnal PubMed search
was performed on 30 November 2011. The Athens website
was also used to search the UK MEDLINE Database,
EMBASE and CINAHL Databases. The search was
performed on 30 November. A full review of the search
strategy is provided in online appendix 1. No limits were
placed on the search using either the PubMed portal or
the Athens portal with regard to year range, age range or
language. Third, a search for randomised controlled trials
was performed using the Cochrane Database. A full review
of the search strategy is provided in online appendix 1.
Selection criteria were broadly based upon MOOSE,
9
methodology. Inclusion criteria were (1) randomised
controlled trials comparing patients with aspirin-related
ICH (spontaneous or traumatic) who were treated with
a platelet transfusion compared with those with aspirin-
related ICH who were not treated with a platelet trans-
fusion. (2) Caseecontrol studies comparing mortality
rates of adult head injury patients on antiplatelet agents
(with ICH) who received a platelet transfusion versus
mortality rates of adult head injury patients on anti-
platelet agents (with ICH) who did not receive a platelet
transfusion. No lower limit was placed on the size of the
study groups in either the caseecontrol or nested casee
control studies. (3) Cohort studies with a nested casee
control group comparing mortality rates of adult head
injury patients on antiplatelet agents (with ICH) who
received a platelet transfusion versus mortality rates of
adult head injury patients on antiplatelet agents (with
ICH) who did not receive a platelet transfusion. (4)
Caseecontrol studies or nested caseecontrol studies
comparing mortality rates of adult patients on anti-
platelet agents with spontaneous ICH who received
a platelet transfusion versus mortality rates of adult
patients on antiplatelet agents with spontaneous ICH
who did not receive a platelet transfusion. No lower limit
was placed on the size of the study groups in either the
caseecontrol or nested caseecontrol studies. Appraisal
of the abstract titles for relevance was made by JSB and
AG. All full papers were reviewed by JSB and AG.
Articles were eligible for inclusion from any language
provided that they were published in peer-reviewed jour-
nals. Exclusion criteria: (1) caseecontrol or cohort
studies where patient transfusion was used to correct
a generalised coagulopathy. (2) Caseecontrol or nested
caseecontrol studies in patients with ICH from thrombo-
cytopaenia. All the abstracts and full papers reviewed were
in English language and therefore problems with trans-
lation were not encountered. Conference proceedings
were not included in the search strategy nor was a search
for unpublished data performed. Contact was not made
with authors of any of the studies, and the data were
extracted directly either from the abstract or the full text.
Statistical analysis was performed using Comprehen-
sive Meta-analysis V.2 (http://meta-analysis.com; Biostat
Inc.). Forest plots were produced for the studies with
respect to mortality. Heterogeneity between studies was
performed using the I
2 test.
RESULTS
Six studies were identiﬁed which were found to be suit-
able for the meta-analysis. Two studies were case-
controlled studies in patients with spontaneous ICH and
the remaining four studies were in patients with TICH.
No completed randomised controlled trials were identi-
ﬁed. The inclusion and exclusion PRISMA ﬂow diagram is
shown in ﬁgure 1. A more detailed summary of the results
of the search strategy is shown in online appendix 1.
Characteristics of included studies
Washington and colleagues
10 from Missouri retrospec-
tively reviewed 1101 patients presenting to their level
one trauma centre over a 2-year period with minor
traumatic brain injury (TBI) (Glasgow Coma Scale
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Intracranial haemorrhage, platelet transfusion(GCS) $13). Of these, 321 had TICH and 113 (35.2%)
were on pre-injury antiplatelet agents. The two groups
were similar at baseline in terms of age and presenting
GCS. Primary outcome measures were neurological
decline, Glasgow Outcome Scale, surgical intervention
and mortality. Platelet transfusion was given according to
physician discretion, introducing a risk of bias. The
transfused group had a higher Marshall score, reﬂecting
a larger haematoma volume (20.6626.5 vs 8.2613.7;
p¼0.02), at presentation. There were signiﬁcantly more
patients in the transfused group taking clopidogrel
compared with the non-transfused group (52% vs 20%,
p¼0.0005). They found no statistically signiﬁcant
difference in outcome between the groups; they did ﬁnd
a trend towards signiﬁcance for medical decline
(deﬁned a priori as an increase in the delivered level of
monitoring or intervention because of cardiac, pulmo-
nary or renal decline). Mortality rates were not signiﬁ-
cant between the two groups (2/44 (5%) vs 0/64 (0%)).
They did, however, ﬁnd that of all the TBI patients
included, any patient receiving a transfusion (n¼65,
20%) had a signiﬁcantly higher mortality (6% vs 0%,
p<0.0001) and OR of medical decline (5.8, 95% CI 1.2
to 28.2).
The study by Ducruet et al
11 was a retrospective cohort
study of 66 patients admitted to a neurological ICU with
a primary ICH while on antiplatelet agents. One
hundred ﬁve of the 121 patients were on aspirin alone
and 11 of the 121 patients were taking aspirin and
clopidogrel. Of the remaining ﬁve patients, two were on
dipyridamole and the ﬁnal three not speciﬁed. Of these,
35 (53.8%) received a platelet transfusion. The primary
outcome measure was to detect a 25% difference in
haematoma expansion from the CT on admission
between the platelet-transfused group and the non-
transfused group. Other outcome parameters were the
modiﬁed Rankin Score on discharge, mortality rate and
the rate of systemic complications. The indications for
giving a platelet transfusion were not available to the
investigators, although the assumption was that a platelet
transfusion was given at the discretion of the attending
physician. This may introduce an element of bias into
the study and is to the detriment of the paper. The
groups were well matched with regard to age (p¼0.597)
and mean GCS (p¼0.992). The mortality rate in the
treatment group was half than that in the non-treatment
group; however, due to the small numbers (2/35 (5.7%)
vs 4/31 (12.9%)), the result did not reach statistical
signiﬁcance. They also noted no statistical signiﬁcance in
either initial or ﬁnal haematoma volume (initial volume
(ml) 30.9628.3 vs 27.7625.4, p¼0.63; ﬁnal volume
33.9632.6 vs 33.1630.8, p¼0.92), length of stay or
discharge modiﬁed Rankin score (4.161.3 vs 4.560.9).
The study did suggest a trend towards increased
mortality (23.1% vs 6.1%, p¼0.10) and haematoma
expansion (35.7% vs 11.8%, p¼0.034) in patients taking
clopidogrel rather than those taking aspirin alone.
The Creutzfeldt study
12 was a single-centre retrospec-
tive study of 368 consecutive patients with spontaneous
ICH over 2 years admitted to a primary stroke centre. Of
these, 121 (31.3%) were taking antiplatelet agents
(aspirin 105, clopidogrel 3, aspirin + clopidogrel 11,
aspirin + dipyridamole 2). The primary outcome measure
was hospital death. Secondary outcome measure was
favourable outcome. This study was again well matched
for age (70 vs 71, p¼0.65); however, median GCS (13
(9e15) vs 11 (6.5e14), p¼0.1) was lower at presentation,
suggesting that some of the group not receiving a platelet
transfusion were deemed unsalvageable and palliation
was the preferred treatment pathway, as reﬂected by the
increased Do Not Attempt Resuscitation order frequency
(34% vs 44%). The indications for using a platelet
transfusion were also not available to the investigating
authors, and again, it must be assumed that this was given
at the discretion of the attending physician with the
caveats described above. The mortality rate in the control
group (38%) was quite high in comparison to the other
studies. In the intervention group all 14 patients died,
withdrawl of tretament was performed presumably due to
futility of continuing active management. Due to the
small size of the study, the difference in the mortality rate
between the study group and the control group did reach
statistical signiﬁcance (p¼0.17).
The study by Downey et al
13 was a retrospective review
over 4 years in two level 1 trauma centres. They identi-
ﬁed 328 patients over 50 with TBI on pre-injury anti-
platelet therapy of whom 166 (50.6%) received platelet
transfusion. Primary outcome measure was mortality.
Figure 1 The PRISMA ﬂow diagram.
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Intracranial haemorrhage, platelet transfusionSecondary outcome measure was length of hospital stay.
The two groups were well matched with respect to the
presenting GCS (p¼0.96) but not with respect to age.
Patients who received a platelet transfusion were older
than the control group (p¼0.001). This may reﬂect the
increased prevalence of cardiovascular and cerebrovas-
cular disease in a more elderly population. Thirty-one
patients received a platelet transfusion at the discretion
of the attending surgeon at one centre. At the second
study centre, 135 patients received a platelet transfusion
as part of a routine procedure if the Platelet Function
Analyzer (PFA)-100 screening test showed evidence of
platelet dysfunction. There was little difference in
mortality between the treatment group and the control
group (17.5% vs 16.7%). Additional confounders
include the higher rates of both warfarin use (89% vs
80%, p¼0.038) and clopidogrel use (45% vs 14%,
p<0.001). Unfortunately, the data as described do not
allow separation of these two groups. The warfarin group
had an increased mortality (27.5% vs 15.2%, p¼0.032)
and the clopidogrel group did not (15.5% vs 17.7%,
p¼0.62), which contradicts the ﬁndings of the later
study by Creutzfeldt et al.
12
The Ivascu study
14 was a retrospective review of
a trauma registry over a 5-year period of patients with ICH
who were taking pre-injury antiplatelet agents. In total,
109 patients were identiﬁed: 61 patients were on aspirin,
17 patients were on clopidogrel and 31 patients were on
both. Of these 109 patients, 40 (36.7%) were given
a platelet transfusion, again at the discretion of the
attending physician. The primary outcome measure was
mortality. The cohort of patients in this study were
reasonably well matched with regard to age (p¼0.593)
and presenting GCS (p¼0.332). The Injury Severity Score
was slightly higher in the transfusion group than in the
control group (23.469.8 vs 20.366.7, p¼0.183). This may
be the explanation for the sizeable difference in the
mortality between the two groups with the higher
mortality being in the transfusion group (27.5% vs 13.0%,
p¼0.064), as may also explain the increased proportion in
the transfusion group operated upon compared with the
non-transfused group (9/40 (22.5%) vs 8/69 (11.5%)),
p¼0.137).
The Fortuna study
15 was a retrospective review of
patients with TBI aged over 50 years in a single, tertiary,
level 1 trauma centre. They identiﬁed 521 patients ﬁtting
these criteria but acknowledge that they did exclude
patients in whom the medical records were incomplete.
Of the 521 patients, 166 were taking pre-injury anti-
platelet and anticoagulant therapy. One hundred and
twenty-six patients were taking antiplatelet agents (17
clopidogrel, 91 aspirin and 18 were taking both). Twenty-
nine patients were taking warfarin and 11 patients
‘other’ unspeciﬁed medication. Sixty-six (39.8%) of
these 166 patients received a platelet transfusion during
their stay. Patients receiving a platelet transfusion were
older (7362v s6 9 61, p¼0.02), had a lower initial GCS
(1161v s1 3 60.2, p¼0.004), a higher initial Injury
Severity Score (ISS) (2861v s2 4 61, p¼0.001) and
a longer length of stay (1262v s7 60.4 days, p¼0.007);
all these may have contributed to the higher mortality
(20/66, 30.3%) compared with those in the group which
did not receive a platelet transfusion (16/100, 16%). As
with many of the preceding papers, the platelets were
given at the discretion of the attending physician.
A comparison of the studies by age, mean GCS and
mortality rates are provided in tables 1e3, respectively.
Meta-analysis data
Forest plots were produced for the mortality rates in the
intervention (transfusion) and control groups (ﬁgure 2).
Separate Forest plots were produced for traumatic and
spontaneous ICH. These are included as ﬁgures 3 and 4.
Signiﬁcant heterogeneity was present between the six
studies, I
2¼58.276; therefore, the random effects model
Table 2 Comparison of studies by mean Glasgow Coma
Scale (GCS)
Author











11 11.863.8 11.863.7 0.992
Creutzfeldt et al
12 13z 11z 0.10
Downey et al
13 NQx NQx 0.96
Ivascu et al
14 13.563.0 13.762.8 0.676
Fortuna et al
15 11611 3 60.2 0.004
*Mean GCS value calculated by Batchelor and Grayson.
yp Value Wilcoxon’s test calculated by Washington et al.
10
zMedian ﬁrst GCS score.
xNQ: mean values not quoted only p value given.
Table 1 Comparison of studies by mean age
Author






10 74.3611.7 75.4612.3 0.63
Ducruet et al
11 73.2610.1 71.7613.5 0.597
Creutzfeldt et al
12 70 71 0.65
Downey et al
13 77.4 73.0 <0.001
Ivascu et al
14 87.2610.5 76.869 0.473
Fortuna et al
15 73626 8 61 0.02
Table 3 Mortality rates for the six studies
Author
Mortality Mortality
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Intracranial haemorrhage, platelet transfusionwas the preferred model and this produced a pooled OR
for survival of 0.773 (95% CI 0.414 to 1.442). The ﬁxed
effects model was also evaluated and this was found to
produce a similar results (common OR for survival:
0.798, 95% CI 0.559 to 1.139). The ﬁxed effect model for
the spontaneous-only group produced a pooled OR of
1.825 (95% CI 0.892 to 3.744). The ﬁxed effect model
for the trauma-only group produced a pooled OR of
0.609 (95% CI 0.404 to 0.917).
DISCUSSION
Six studies were identiﬁed for the meta-analysis, two
studies evaluating patients with spontaneous ICH and
four with TICH. Combining the data from all studies,
there was no evidence of beneﬁt, with a trend towards
decreased survival in patients selected for a platelet
transfusion. All six studies were relatively small in size,
this combined with the difference in pathophysiology of
traumatic ICH and spontaneous ICH makes any clear
conclusions prohibitive.
When the data for TICH are extracted separately,
platelet transfusions appear to have a negative effect on
survival 0.609 (95% CI 0.404 to 0.917). The paper by
Downey et al
13 had the greatest weight in the meta-
analysis data because of its greater numbers. The paper
by Downey et al
13 was judged by both authors to be the
weakest due to differing protocols followed on either
site (treatment at physician discretion vs treatment
according to platelet function). If this paper is removed,
the risk of survival from platelet transfusion decreases
further (OR 0.387, 95% CI 0.216 to 0.694); how much
weight can be given to this due to the reduction of
patient numbers by 46% is unclear. The fact that platelet
transfusions were given at the discretion of the attending
surgeon does add signiﬁcant bias into the meta-analysis.
Although the studies were reasonably controlled with
respect to presenting GCS, other factors such as
increased haematoma volume or associated co-morbidity
may have contributed to the worse outcome in the
platelet transfusion group rather than the platelet
transfusion itself. There may be a caveat for transfusing
patients on antiplatelet agents who have sustained
a traumatic ICH, although further work is required in
this area.
Conversely, patients with spontaneous ICH showed
a trend towards beneﬁt from platelet transfusion (OR
1.825, 95% CI 0.892 to 3.734). This was despite the small
study numbers and allocation of patients at physician
discretion, possibly introducing a positive bias in terms
of both severity and therefore presumed survivability.
With the assumption that patients considered more
likely to survive were more likely to be given a platelet
transfusion and vice versa. A subgroup analysis, Ducruet
et al,
11 also showed that in the subgroup of patients on
clopidogrel, there was an increased mortality and an
increase in haematoma expansion.
With regard to spontaneous ICH, three important
papers relevant to this subject need to be discussed.
Sansing et al
16 undertook a retrospective cohort study
on 282 patients with spontaneous ICH, 70 patients were
on antiplatelet medication. The authors found no
difference between the antiplatelet medication group
and the no antiplatelet group with regard to volume of
ICH on CT, haematoma growth or outcome score.
Figure 2 The forest plot for the
six studies. Random effect model.
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Intracranial haemorrhage, platelet transfusionNaidech et al
17 performed a cohort study on 68 patients
with spontaneous ICH who were either on antiplatelet
agents or had laboratory evidence of reduced platelet
function. A platelet transfusion was administered in 16
patients at the discretion of the attending physician.
The authors found that there was no difference in the
modiﬁed Rankin Scale at 14 days, 28 days and 3 months
between the transfused group and the non-transfused
group. Naidech et al
18 published their ﬁndings from
a prospective cohort study on 45 patients with sponta-
neous ICH and reduced platelet activity. The cohort was
divided into high risk for haemorrhage growth grade
and non-high-risk patients for haemorrhage growth.
High-risk patients received a CTand platelet transfusion
within 12 h of symptom onset. Non-high-risk patients
received a CT and platelet transfusion after 12 h. The
authors found that for the high-risk group platelet
transfusion within 12 h resulted in smaller haemorrhage
size and better outcome (modiﬁed Rankin Score)
compared with the cohort of patients who received
a platelet transfusion after 12 h. Further work is required
in some of these areas, in particular to clarify the effect of
pre-injury antiplatelet agents on haematoma size and
progression.
With regard to the traumatic ICH cohort, a relevant
paper was published by Bachelani et al
19. Theses authors
performed a nested caseecontrol study comparing
aspirin-associated TICH against a control group of non-
aspirin-associated ICH. The Aspirin Response Test (ART;
VerifyNow) was performed on all patients. Patients with
an ART <550 received a platelet transfusion. Eleven
patients in the non-aspirin control group (n¼48) had an
ART evidence of platelet inhibition and consequently
received a platelet transfusion. Two patients in the
aspirin group (n¼36) had no ART evidence of platelet
inhibition and therefore did not receive a platelet
transfusion. The data were therefore not suitable for this
meta-analysis. Bachelani et al,
19 however, found no
difference in mortality between the aspirin group and
the non-aspirin group.
CONCLUSIONS
The small size of the six studies none of which were
powered to demonstrate a difference in survival clearly
means that no ﬁrm conclusions can be drawn from this
meta-analysis. Except for the study by Downey et al,
13
platelet transfusion in the remaining studies were given
at the discretion of the attending surgeon. The current
low level of evidence has prompted a multiple centre
randomised control trial based in the Netherlands, The
PATCH study,
20 in order to address the potential efﬁcacy
of platelet transfusion in patients with antiplatelet-asso-
ciated ICH. The end points of the study are safety of
platelet transfusion and haematoma progression.
Further work is clearly required on this subject so that
the efﬁcacy of platelet transfusion in spontaneous or
traumatic ICH can be fully evaluated.
Acknowledgements The authors would like to thank Katherine Wylie Senior
Informaticist, Department of Emergency Medicine, Manchester Royal
Inﬁrmary, for her assistance with the Cochrane Search.
Contributors JSB reviewed all the abstracts, reviewed all the full papers,
performed the statistical analysis and wrote the paper. AG also reviewed all
the abstract titles for relevance. AG also reviewed the papers selected for the
meta-analysis and undertook a substantial part in the preparation of the
revised manuscript.
Funding This research received no speciﬁc grant from any agency in the
public, commercial or not-for-proﬁt sectors.
Competing interests None.
Provenance and peer review Not commissioned; externally peer reviewed.
Data sharing statement There are no additional data available.
REFERENCES
1. He J, Whelton PK, Vu B, et al. Aspirin and risk of hemorrhagic stroke.
JAMA 1998;280:1930e5.
2. Mack LR, Chan SB, Silva JC, et al. The use of head computed
tomography in elderly patients sustaining minor head trauma. J
Emerg Med 2003;24:157e62.
3. Spektor S, Agus S, Merkin V, et al. Low-dose aspirin prophylaxis and
risk on intracranial haemorrhage in patients older than 60 years of age
with mild or moderate head injury: a prospective study. J Neurosurg
2003;99:661e5.
4. Jones K, Sharp C, Mangram AJ, et al. The effect of preinjury
clopidogrel use on older trauma patients with head injuries. Am J Surg
2006;192:743e5.
5. Fabbri A, Servadei F, Marchesini G, et al. Predicting intracranial
lesions by antiplatelet agents in subjects with mild head injury. J
Neurol Neurosurg Psych 2010;81:1275e9.
6. McMillian WD, Rogers FB. Management of prehospital antiplatelet
and anticoagulant therapy in traumatic head injury: a review. J
Trauma 2009;66:942e50.
7. Beshay JE, Morgan H, Madden C, et al. Emergency Reversal of
anticoagulation and antiplatelet therapies in neurosurgical patients. J
Neurosurg 2010;112:307e18.
8. Campbell PG, Sen A, Yadla S, et al. Emergency Reversal of
antiplatelet agents in patients presenting with an intracranial
haemorrhage: a Clinical Review. World Neurosurg 2010;74:279e85.




6 Batchelor JS, Grayson A. BMJ Open 2012;2:e000588. doi:10.1136/bmjopen-2011-000588
Intracranial haemorrhage, platelet transfusion9. Stroup DF, Berlin JA, Morton SC, et al. Meta-analysis of
Observational studies in Epidemiology (MOOSE) group. JAMA
2000;283:2008e12.
10. Washington CW, Schuerer DJ, Grubb R. Platelet transfusion: an
unnecessary risk for mild traumatic brain injury patients on antiplatelet
therapy. J Trauma 2011;71:358e63.
11. Ducruet AF, Hickman ZL, Zacharia BE, et al. Impact of platelet
transfusion on hematoma expansion in patients receiving antiplatelet
agents before intracerebral hemorrhage. Neurol Res
2010;32:706e10.
12. Creutzfeldt CT, Weinstein JR, Longstreth WT, et al. Prior antiplatelet
therapy, platelet infusion therapy, and outcome after intracerebral
hemorrhage. J Stroke Cerebrovasc Dis 2009;18:221e8.
13. Downey DM, Monson B, Butler KL, et al. Does platelet administration
affect mortality in elderly head-injured patients taking antiplatelet
medication? Am Surg 2009;75:1100e3.
14. Ivascu FA, Howells GA, Junn FS, et al. Predictors of mortality in
trauma patients with intracranial haemorrhage on preinjury aspirin or
clopidogrel. J Trauma 2008;65:785e8.
15. Fortuna GR, Mueller EW, James LE, et al. The impact of preinjury
antiplatelet and anticoagulant pharmacotherapy on outcomes in
elderly patients with haemorrhagic brain injury. Surgery
2008;144:598e603.
16. Sansing LH, Messe SR, Cucchiara BL, et al. Prior antiplatelet use
does not affect hemorrhage growth or outcome after ICH. Neurol
2009;72:1397e402.
17. Naidech AM, Jovanovic B, Liebling S, et al. Reduced platelet activity
is associated with early clot growth and worse 3-month outcome after
intracerebral haemorrhage. Stroke 2009;40:2398e401.
18. Naidech AM, Liebling SM, Rosenberg NF, et al. Early platelet
transfusion improves platelet activity and may improve outcomes
after intracerebral hemorrhage. NeuroCrit Care 2012;16:82e7.
19. Bachelani AM, Bautz JT, Sperry JL, et al. Assessment of platelet
transfusion for reversal of aspirin after traumatic brain injury. Surgery
2011;150:836e43.
20. de Gans K, de Haan RJ, Majoie CB, et al. Patch Study: platelet
transfusion in cerebral haemorrhage; study protocol for a multicentre,
randomised, control trial. BMC Neurol 2010;10:19.
Batchelor JS, Grayson A. BMJ Open 2012;2:e000588. doi:10.1136/bmjopen-2011-000588 7
Intracranial haemorrhage, platelet transfusion